Getting your Trinity Audio player ready...
|
Peraso Inc. (NASDAQ: PRSO) Rides Military AI Boom as Defense Spending Surges – More Stocks Inside
As global defense spending surges, investors are turning their attention to AI-driven military technologies, fueling demand for secure, high-speed communication systems. Peraso Inc. (NASDAQ: PRSO) is emerging as a key player in this evolving sector, leveraging its millimeter wave (mmWave) technology to provide low-latency, interference-free communications, critical for military drone surveillance, real-time battlefield intelligence, and defense networking. With defense agencies prioritizing next-gen connectivity solutions, PRSO stands poised for potential military contracts and strategic partnerships. Also AI-powered biotech stocks gaining attention, mentioned inside this article.
Financial & Market Indicators:
- Defense Spending Growth: The U.S. defense budget exceeded $850 billion in 2024, with AI-driven military projects receiving increased funding for advanced communication and security solutions—a sector where Peraso’s mmWave technology thrives.
- Comparison to GSI Technology (NASDAQ: GSIT): GSIT, which specializes in AI-powered military computing, saw a 43% surge after securing a U.S. Army contract, underscoring the market potential for similar small-cap stocks like PRSO.
- Potential for Military Contracts: PRSO’s mmWave solutions align with government and defense agency needs, making it a top contender for future defense technology contracts.
Why PRSO is a Smart Play for Defense Investors:
- High-Security Communication: PRSO’s mmWave technology is resistant to jamming and interference, making it ideal for military drone operations and secure battlefield intelligence.
- Growing Industry Momentum: As military AI adoption accelerates, investors are seeking defense-tech crossover stocks, positioning PRSO as a rare, publicly traded player in this space.
- Small-Cap Growth Potential: Unlike large-cap defense stocks, PRSO remains undervalued, giving early investors a chance to capitalize on its emerging role in AI-powered defense technology.
Additional Market Movers to Watch:
- Kairos Pharma (NYSE: KAPA) is pioneering immune-suppression resistant cancer therapeutics, with a pipeline targeting prostate cancer, lung cancer, breast cancer, and glioblastoma.
- Quantum BioPharma (NASDAQ: QNTM) confirmed its supplement unbuzzd™ accelerates alcohol metabolism, reducing BAC by over 40% in 30 minutes, improving alertness and cognitive function.
- Evaxion Biotech (NASDAQ: EVAX) closed a $10.8 million public offering to advance its AI-powered cancer immunotherapy candidates, backed by Merck’s MSD Global Health Innovation Fund.
- Invivyd (NASDAQ: IVVD) reported positive Phase 1/2 clinical data for VYD2311, a long-acting alternative to COVID-19 vaccines, with 17x greater neutralization potency than pemivibart.
- · CS Diagnostics Corp. (OTCQB: CSDX) launches MEDUSA, a next-gen smart disinfectant with up to 10 days of surface protection, EU and UAE approvals, pending U.S. clearance, and a projected $80M revenue by 2025, aiming for 10% of the $8.37B global disinfectant market.
As defense budgets rise and AI-driven military tech advances, PRSO’s mmWave solutions present a strong investment opportunity in the defense-tech sector. Meanwhile, AI-powered biotech stocks like KAPA, QNTM and EVAX, are gaining traction in next-gen immunotherapy and antibody treatments, highlighting AI’s impact on healthcare. With potential military contracts and industry momentum, PRSO is poised for breakout growth, making it a top watchlist stock alongside KAPA, QNTM, IVVD, EVAX, CSDX and GSIT.